AstraZeneca's Imfinzi Immunotherapy Gets U.S. FDA Approval for Endometrial Cancer
By Elena Vardon
AstraZeneca said the U.S. Food and Drug Administration approved the use of its Imfinzi immunotherapy along with chemotherapy for endometrial cancer.
The British-Swedish pharma giant said Monday that it received approval in the U.S. for the drug--in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy--to be used to treat adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.
The FDA gave the group the green light based on the results of its DUO-E Phase 3 trial, which showed Imfinzi reduced the risk of disease progression or death by 58% against chemotherapy alone, AstraZeneca said.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
June 17, 2024 02:29 ET (06:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now